Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

EPOPROSTENOL vs ERDAFITINIB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

EPOPROSTENOL vs ERDAFITINIB: Safety Overview

Metric EPOPROSTENOL ERDAFITINIB
Total FAERS Reports 13,322 1,106
Deaths Reported 2,713 315
Death Rate 20.4% 28.5%
Hospitalizations 8,838 226
Average Patient Age 49.9 yrs 66.6 yrs
% Female Patients 78.1% 37.9%
FDA Approval Date Apr 23, 2008 Apr 12, 2019
Manufacturer Mylan Institutional LLC Janssen Products LP
Route INTRAVENOUS ORAL
Marketing Status Discontinued Prescription